Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

One day after a double-pronged loss in prostate and lung cancer, Merck & Co.’s immuno-oncology superstar Keytruda is bouncing back. In the phase 3 Keynote-671 study, Keytruda hit one of two primary ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

Merck’s immuno-oncology blockbuster Keytruda was mentioned more than a dozen times in the company’s third-quarter earnings announcement, and not just because sales of the drug soared 62% to $3.1 ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma. Keytruda (pembrolizumab) elicited ...

CHICAGO — For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for ...

LOS ANGELES (KABC) -- Researchers call the drug Keytruda a new and exciting option in treating the leading cause of cancer deaths worldwide. One local lung cancer patient experienced what doctors ...

For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds A large clinical trial shows that for many patients with the most common type of lung cancer, ...